Maria Martelo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Martelo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- André Mansinho
START Lisbon Unidade Local de Saúde Santa Maria Lisbon Portugal
10 shared publications - Catarina Abreu
Medical Oncology Department, Unidade Local de Saúde Santa Maria, 1649-035 Lisboa, Portugal
10 shared publications - Eva González-Suárez
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
10 shared publications - Eva Maria Trinidad
Oncobell, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain
10 shared publications - Inês Gomes
Oncology Translational Laboratory, GIMM - Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal
10 shared publications - Joana L. Miranda
Oncology Translational Laboratory, GIMM - Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal
10 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Table 1. Molecular characteristics of the human cell lines used in this study.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Table 1. Molecular characteristics of the human cell lines used in this study.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Table 5. HALLMARK gene set enrichment analysis (GSEA_mh) of mouse allografts (NES>1.5 or <-1.5; NOM p value<0.05; FDR q value<0.25).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Table 5. HALLMARK gene set enrichment analysis (GSEA_mh) of mouse allografts (NES>1.5 or <-1.5; NOM p value<0.05; FDR q value<0.25).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Figure 1 (related to Fig. 1). RANK pathway inhibition sensitizes TNBC cells to CDK4/6i. A, RT–qPCR analysis of RANK in TNBC cell lines (n = 2-3 biological replicates). B, RT–qPCR analysis of RANK in parental, shControl and shRANK MDA-MB-231 cells (n = 3 biological replicates). Western blot analysis of C, p-ERK1/2, D, p-p65 and p-AKT after 15 min of stimulation with 1 μg/mL RANKL neutralized or not with 2.5 μg/mL RANKLi (OPG-Fc or RANK-Fc), with β-actin as a loading control. E, Viability of the indicated cell lines cultured for 7 days in the presence of increasing concentrations of CDK4/6i ± 100 ng/mL OPG-Fc, as measured by the Alamar blue assay (n = 3-4 independent experiments). F, Proliferation of the indicated cell lines cultured in the presence of 1 μM CDK4/6i ± 100 ng/mL RANK-Fc for 7 days and in drug-free media for an additional 7 days, as measured by clonogenic assay (n = 3-6 independent experiments). G, Cell cycle analysis in MDA-MB-231 cell lines cultured with 100 ng/mL OPG-Fc for 7 days (n = 3 independent experiments). The results are presented as the means ± SEMs. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Figure 1 (related to Fig. 1). RANK pathway inhibition sensitizes TNBC cells to CDK4/6i. A, RT–qPCR analysis of RANK in TNBC cell lines (n = 2-3 biological replicates). B, RT–qPCR analysis of RANK in parental, shControl and shRANK MDA-MB-231 cells (n = 3 biological replicates). Western blot analysis of C, p-ERK1/2, D, p-p65 and p-AKT after 15 min of stimulation with 1 μg/mL RANKL neutralized or not with 2.5 μg/mL RANKLi (OPG-Fc or RANK-Fc), with β-actin as a loading control. E, Viability of the indicated cell lines cultured for 7 days in the presence of increasing concentrations of CDK4/6i ± 100 ng/mL OPG-Fc, as measured by the Alamar blue assay (n = 3-4 independent experiments). F, Proliferation of the indicated cell lines cultured in the presence of 1 μM CDK4/6i ± 100 ng/mL RANK-Fc for 7 days and in drug-free media for an additional 7 days, as measured by clonogenic assay (n = 3-6 independent experiments). G, Cell cycle analysis in MDA-MB-231 cell lines cultured with 100 ng/mL OPG-Fc for 7 days (n = 3 independent experiments). The results are presented as the means ± SEMs. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Figure 2 (related to Fig. 2). Palbociclib in combination with OPG-Fc restrains tumor growth in vivo. A, IHC analysis of ER, HER2, p-pRb and RANK in PDX tissue, including positive cell line-derived xenograft tissue as positive control for ER and HER2, and representative images at 400X magnification. B, Single tumor growth curves (all treated animals independently of treatment completion, n = 4-5 animals, n = 8-10 tumors in the cell line-derived model, and n = 3-4 animals in the PDX model). Tumors were measured externally with a caliper at the indicated time points, and Tvol = 1/2 (length × width2) was calculated. C, Tumor weight at sacrifice (n = 6-8 tumors in the cell line-derived model, and n = 3-4 tumors in the PDX model). D, Mouse body weight during treatment (n = 3-5 animals). E, Quantification of TRAcP5b in mouse serum by ELISA (n = 2-4 samples/group). F, Venn diagram depicting the overlap between DEGs of MDA-MB-231 tumors treated with OPG-Fc (n = 2), palbociclib (Palbo, n = 2) or palbociclib + OPG-Fc (COMB, combination, n = 3) in comparison with vehicle (Veh, n = 3). The results are presented as the means ± SEMs. *p < 0.05, **p < 0.01.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Figure 2 (related to Fig. 2). Palbociclib in combination with OPG-Fc restrains tumor growth in vivo. A, IHC analysis of ER, HER2, p-pRb and RANK in PDX tissue, including positive cell line-derived xenograft tissue as positive control for ER and HER2, and representative images at 400X magnification. B, Single tumor growth curves (all treated animals independently of treatment completion, n = 4-5 animals, n = 8-10 tumors in the cell line-derived model, and n = 3-4 animals in the PDX model). Tumors were measured externally with a caliper at the indicated time points, and Tvol = 1/2 (length × width2) was calculated. C, Tumor weight at sacrifice (n = 6-8 tumors in the cell line-derived model, and n = 3-4 tumors in the PDX model). D, Mouse body weight during treatment (n = 3-5 animals). E, Quantification of TRAcP5b in mouse serum by ELISA (n = 2-4 samples/group). F, Venn diagram depicting the overlap between DEGs of MDA-MB-231 tumors treated with OPG-Fc (n = 2), palbociclib (Palbo, n = 2) or palbociclib + OPG-Fc (COMB, combination, n = 3) in comparison with vehicle (Veh, n = 3). The results are presented as the means ± SEMs. *p < 0.05, **p < 0.01.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Table 4. HALLMARK gene set enrichment analysis (H-GSEA) of mouse xenografts (NES>1 or <-1; NOM p value<0.05; FDR q value<0.25).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Table 4. HALLMARK gene set enrichment analysis (H-GSEA) of mouse xenografts (NES>1 or <-1; NOM p value<0.05; FDR q value<0.25).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Differentially expressed genes (DEGs) between treated (OPG-Fc n = 2; Palbo n = 2; COMB n = 3) and untreated (Vehicle, n = 3) MDA-MB-231 xenografts, ranked according to Log2FC (log2>1 or <-1; FDR q value<0.1). (.xls file)
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Differentially expressed genes (DEGs) between treated (OPG-Fc n = 2; Palbo n = 2; COMB n = 3) and untreated (Vehicle, n = 3) MDA-MB-231 xenografts, ranked according to Log2FC (log2>1 or <-1; FDR q value<0.1). (.xls file)
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Despite chemotherapy’s limitations and toxic effects, it remains the primary treatment for most patients with triple-negative breast cancer (TNBC), with or without immune checkpoint inhibitors. Although cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have revolutionized luminal breast cancer treatment, CDK4/6is alone are largely ineffective in TNBC, even with functional retinoblastoma protein (pRB). Activation of the receptor activator of nuclear factor κB (RANK) pathway has been associated with poor prognosis in TNBC and with resistance to CDK4/6is in luminal breast cancer, effects that can be reversed by RANK ligand inhibitors (RANKLi). In this study, we analyzed the effect of RANK knockdown or RANKLi in the response of pRB-proficient TNBC to CDK4/6i in vitro. RANK + patient-derived xenograft and cell line–derived xenograft models were used to assess therapeutic efficacy of CDK4/6i + RANKLi in vivo. Two syngeneic models of TNBC and luminal breast cancer were used to portrait the main therapy-induced alterations in the tumor immune microenvironment. RANK knockdown or RANKLi sensitized pRB-proficient TNBC cells to CDK4/6i in vitro. The combination of palbociclib and RANKLi regressed or prevented tumor growth and metastasis in vivo, enhancing cell cycle arrest. Both CDK4/6i and RANKLi elicited an antitumor immune response, characterized by an increase in CD4+ and CD8+ T cells and a decrease in tumor-associated macrophages infiltrating the tumor microenvironment. These findings suggest that combining CDK4/6i and RANKLi could offer a new therapeutic strategy for pRB-proficient TNBC, holding potential immunomodulatory benefits across breast cancer subtypes.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Despite chemotherapy’s limitations and toxic effects, it remains the primary treatment for most patients with triple-negative breast cancer (TNBC), with or without immune checkpoint inhibitors. Although cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have revolutionized luminal breast cancer treatment, CDK4/6is alone are largely ineffective in TNBC, even with functional retinoblastoma protein (pRB). Activation of the receptor activator of nuclear factor κB (RANK) pathway has been associated with poor prognosis in TNBC and with resistance to CDK4/6is in luminal breast cancer, effects that can be reversed by RANK ligand inhibitors (RANKLi). In this study, we analyzed the effect of RANK knockdown or RANKLi in the response of pRB-proficient TNBC to CDK4/6i in vitro. RANK + patient-derived xenograft and cell line–derived xenograft models were used to assess therapeutic efficacy of CDK4/6i + RANKLi in vivo. Two syngeneic models of TNBC and luminal breast cancer were used to portrait the main therapy-induced alterations in the tumor immune microenvironment. RANK knockdown or RANKLi sensitized pRB-proficient TNBC cells to CDK4/6i in vitro. The combination of palbociclib and RANKLi regressed or prevented tumor growth and metastasis in vivo, enhancing cell cycle arrest. Both CDK4/6i and RANKLi elicited an antitumor immune response, characterized by an increase in CD4+ and CD8+ T cells and a decrease in tumor-associated macrophages infiltrating the tumor microenvironment. These findings suggest that combining CDK4/6i and RANKLi could offer a new therapeutic strategy for pRB-proficient TNBC, holding potential immunomodulatory benefits across breast cancer subtypes.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Figure 3 (related to Fig. 3). Palbociclib in combination with OPG-Fc decreases the growth of palbociclib-resistant tumors in vivo and induces an inflammatory response. A, Rank expression in murine BC cell lines retrieved from CCLE (n = 4). B, Proliferation of the indicated cell lines cultured in the presence of CDK4/6i for 7 days and in drug-free media for an additional 7 days, as measured by a clonogenic assay (n = 3-4 independent experiments). C, Tumor weight at sacrifice (n = 4-8 tumors). D, Quantification of TRAcP5b in mouse serum by ELISA (n = 3 samples/group). E, Mouse body weight during treatment (n = 4-5 animals). The results are presented as the means ± SEMs. *p < 0.05, **p < 0.01.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Figure 3 (related to Fig. 3). Palbociclib in combination with OPG-Fc decreases the growth of palbociclib-resistant tumors in vivo and induces an inflammatory response. A, Rank expression in murine BC cell lines retrieved from CCLE (n = 4). B, Proliferation of the indicated cell lines cultured in the presence of CDK4/6i for 7 days and in drug-free media for an additional 7 days, as measured by a clonogenic assay (n = 3-4 independent experiments). C, Tumor weight at sacrifice (n = 4-8 tumors). D, Quantification of TRAcP5b in mouse serum by ELISA (n = 3 samples/group). E, Mouse body weight during treatment (n = 4-5 animals). The results are presented as the means ± SEMs. *p < 0.05, **p < 0.01.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Table 3. KEGG pathway and GO_P enrichment analysis of DEGs (NOM p value<0.05; FDR q value<0.25).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Supplementary Table 3. KEGG pathway and GO_P enrichment analysis of DEGs (NOM p value<0.05; FDR q value<0.25).
- 30 May 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (11) , 1826-1838
RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Despite chemotherapy’s limitations and toxic effects, it remains the primary treatment for most patients with triple-negative breast cancer (TNBC), with or without immune checkpoint inhibitors. Although cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have revolutionized luminal breast cancer treatment, CDK4/6is alone are largely ineffective in TNBC, even with functional retinoblastoma protein (pRB). Activation of the receptor activator of nuclear factor κB (RANK) pathway has been associated with poor prognosis in TNBC and with resistance to CDK4/6is in luminal breast cancer, effects that can be reversed by RANK ligand inhibitors (RANKLi). In this study, we analyzed the effect of RANK knockdown or RANKLi in the response of pRB-proficient TNBC to CDK4/6i in vitro. RANK + patient-derived xenograft and cell line–derived xenograft models were used to assess therapeutic efficacy of CDK4/6i + RANKLi in vivo. Two syngeneic models of TNBC and luminal breast cancer were used to portrait the main therapy-induced alterations in the tumor immune microenvironment. RANK knockdown or RANKLi sensitized pRB-proficient TNBC cells to CDK4/6i in vitro. The combination of palbociclib and RANKLi regressed or prevented tumor growth and metastasis in vivo, enhancing cell cycle arrest. Both CDK4/6i and RANKLi elicited an antitumor immune response, characterized by an increase in CD4+ and CD8+ T cells and a decrease in tumor-associated macrophages infiltrating the tumor microenvironment. These findings suggest that combining CDK4/6i and RANKLi could offer a new therapeutic strategy for pRB-proficient TNBC, holding potential immunomodulatory benefits across breast cancer subtypes.
- 30 May 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (11) , 1826-1838
RANK Pathway Inhibition Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibitors and Enhances Immune Response
Despite chemotherapy’s limitations and toxic effects, it remains the primary treatment for most patients with triple-negative breast cancer (TNBC), with or without immune checkpoint inhibitors. Although cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have revolutionized luminal breast cancer treatment, CDK4/6is alone are largely ineffective in TNBC, even with functional retinoblastoma protein (pRB). Activation of the receptor activator of nuclear factor κB (RANK) pathway has been associated with poor prognosis in TNBC and with resistance to CDK4/6is in luminal breast cancer, effects that can be reversed by RANK ligand inhibitors (RANKLi). In this study, we analyzed the effect of RANK knockdown or RANKLi in the response of pRB-proficient TNBC to CDK4/6i in vitro. RANK + patient-derived xenograft and cell line–derived xenograft models were used to assess therapeutic efficacy of CDK4/6i + RANKLi in vivo. Two syngeneic models of TNBC and luminal breast cancer were used to portrait the main therapy-induced alterations in the tumor immune microenvironment. RANK knockdown or RANKLi sensitized pRB-proficient TNBC cells to CDK4/6i in vitro. The combination of palbociclib and RANKLi regressed or prevented tumor growth and metastasis in vivo, enhancing cell cycle arrest. Both CDK4/6i and RANKLi elicited an antitumor immune response, characterized by an increase in CD4+ and CD8+ T cells and a decrease in tumor-associated macrophages infiltrating the tumor microenvironment. These findings suggest that combining CDK4/6i and RANKLi could offer a new therapeutic strategy for pRB-proficient TNBC, holding potential immunomodulatory benefits across breast cancer subtypes.